Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brazil launches major study to track severe COPD outcomes

NCT ID NCT06780046

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 11, 2026 · Updated 6 times

Summary

This study will follow 693 people in Brazil with severe or very severe COPD to track how often they are hospitalized, have flare-ups, or die. Researchers want to understand the real-world impact of the disease in this group. No new treatments are being tested—only data is collected.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide much-needed data on how severe COPD progresses in Brazilian patients, helping doctors better manage the disease.
What could go wrong
This is an observational study, not a treatment trial. It only collects data, so it won't directly improve health. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 693 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults of both sexes with severe and very severe COPD being followed up at participating centers - referral hospitals distributed throughout the country. There are plans to include 693 patients from GOLD B, E, 3 and 4, who will be followed up for 12 months.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients of both sexes, aged 18 years or older, with confirmed COPD according to GOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT \>=10); or * GOLD E (\>=2 moderate or 1 severe exacerbation - hospitalization); or * GOLD 3 and 4 (FEV1 \<50%). Exclusion Criteria: * Advanced fibrosing interstitial lung disease (extent \>=50%); and/or * High-risk pulmonary hypertension (on triple therapy); and/or * Active cancer - on systemic therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (chronic obstructive pulmonary disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD (chronic obstructive pulmonary disease)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Aparecida de Goiânia, Brazil

  • Research Site

    RECRUITING

    Bahia, Brazil

  • Research Site

    RECRUITING

    Belém, Brazil

  • Research Site

    RECRUITING

    Brasília, Brazil

  • Research Site

    RECRUITING

    Campo Grande, Brazil

  • Research Site

    RECRUITING

    Florianópolis, Brazil

  • Research Site

    RECRUITING

    Goiânia, Brazil

  • Research Site

    RECRUITING

    Santo André, Brazil

  • Research Site

    RECRUITING

    São Paulo, Brazil

  • Research Site

    RECRUITING

    Uberlândia, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.